

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

## **SUPPLEMENTAL ANNOUNCEMENT FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022**

Reference is made to the annual report of Joinn Laboratories (China) Co., Ltd. (北京昭衍新藥研究中心股份有限公司) (the “**Company**”) for the year ended 31 December 2022 (the “**2022 Annual Report**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the 2022 Annual Report.

### **PRE-IPO SHARE OPTION AND RESTRICTED AWARD SCHEMES**

In addition to the information disclosed the paragraphs headed “PRE-IPO SHARE OPTION AND RESTRICTED AWARD SCHEMES” under the Report of Directors as set out in the 2022 Annual Report, the Company would like to provide further details regarding the respective awards granted under the 2019 Share Option and Restricted Share Award Scheme and the 2020 Share Option Scheme pursuant to Rule 17.09(3) of the Listing Rules.

The total number of Shares available for issue under the schemes and the percentage of the issued shares that it represents as at the date of the 2022 Annual Report under the 2019 Share Option and Restricted Share Award Scheme and the 2020 Share Option Scheme are set out below:

### **THE 2019 SHARE OPTION AND RESTRICTED SHARE AWARD SCHEME**

**Date of the 2022 Annual Report** **30 March 2023**

#### **Options**

The total number of options available for issue: 40,926

The percentage of the issued Shares that it represents: 0.008%

**Date of the 2022 Annual Report**

**30 March 2023**

**RSUs**

The total number of RSUs available for issue: 3,293

The percentage of the issued Shares that it represents: 0.0006%

**THE 2020 SHARE OPTION SCHEME**

**Date of the 2022 Annual Report**

**30 March 2023**

**Options**

The total number of options available for issue: 1,420,020

The percentage of the issued Shares that it represents: 0.27%

**POST-IPO SHARE INCENTIVE SCHEME AND THE STOCK OWNERSHIP PLAN**

In addition to the information disclosed the paragraphs headed “POST-IPO RESTRICTED SHARE INCENTIVE SCHEME AND THE STOCK OWNERSHIP PLAN” under the Report of Directors as set out in the 2022 Annual Report, the Company would like to provide further details regarding the respective awards granted under the 2021 Restricted A Share Incentive Scheme pursuant to Rule 17.07(1)(c) and Rule 17.07(2) of the Listing Rules.

The following information (underlined for ease of reference) have been added to the table of “LIST OF GRANTEES UNDER THE POST-IPO SHARE OPTION AND RESTRICTED SHARE AWARD SCHEMES” under the Report of Directors: (i) closing price of the Shares of the Company immediately before the dates on which the awards were granted under the 2021 Restricted A Share Incentive Scheme during the Reporting Period; (ii) the fair value of awards at the date of grant; (iii) the exercise period; and (iv) the number of awards available for grant under the 2021 Restricted A Share Incentive Scheme at the beginning and the end of the Reporting Period are set out below:

**LIST OF GRANTEES UNDER THE POST-IPO SHARE OPTION AND RESTRICTED SHARE AWARD SCHEMES**

The following table summarizes the number of underlying A Shares of the outstanding Restricted Shares under the 2021 Restricted A Share Incentive Scheme as at 31 December 2022.

Name of Grantee	Exercise Price (RMB/Share) <sup>(4)</sup>	Date of Grant	Outstanding as at the adoption date (i.e. 19 January 2022)	Grant during the year <sup>(5)(7)</sup>	Exercised during the year <sup>(3)</sup>	Vesting Period and Canceled during the year	Lapsed during the year	Outstanding as at 31 December 2022 <sup>(6)</sup>
Key technical (business) personnel (297 persons)	83.97/59.72	28 January 2022	0	366,300	0	(Notes 1&2)	0	512,820

Notes:

- (1) This batch of outstanding RSUs under the 2021 Restricted A Share Incentive Scheme shall be unlocked in accordance with the unlocking periods as follows: (i) as to 40% of the aggregate number of Restricted Shares between 29 March 2023 and 28 March 2024; (ii) as to 30% of the aggregate number of RSUs between 29 March 2024 and 28 March 2025; and (iii) as to 30% of the aggregate number of RSUs between 29 March 2025 and 28 March 2026.
- (2) **The term of validity of outstanding RSUs shall not exceed 48 months. And the exercise period of outstanding RSUs shall commence from the date on which such restricted shares are no longer under any lock-ups and shall not exceed the validity period.**
- (3) No RSUs were exercised during the reporting period.
- (4) The exercise price of the RSUs have been adjusted for the bonus share issued in August 2022. The Company has issued 4 bonus shares for every 10 shares held. For details, please refer to the announcement made by the Company on 2 August 2022.
- (5) The number of RSUs granted during the reporting period has not been adjusted for the bonus share issued in August 2022.
- (6) The number of outstanding RSUs as at 31 December 2022 has been adjusted in accordance with the bonus share issued in August 2022.
- (7) **The total number of RSUs available for grant under the 2021 Restricted A Share Incentive Scheme was 512,820 and as at 31 December 2022 nil RSU was available for further grant.**
- (8) **The closing price of the Shares immediately before the date of grant of RSUs on 28 January 2022 was RMB97.24. The fair value of the awards was RMB12.91.**
- (9) **The 2021 Restricted A Share Incentive Scheme was adopted on 19 January 2022. Therefore, there is no awards available for grant as at 1 January 2022.**

The above supplemental information does not affect other information contained in the 2022 Annual Report. Save as disclosed above, all other information in the 2022 Annual Report remains unchanged.

By order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC  
10 August 2023

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*